Fda Alerts Article Listing | RxWiki

FDA Alerts

FDA Approves TOBI Podhaler

The US Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.

REFINE

conditions
- - Remove Infectious Disease filter (-) Remove Infectious Disease filter Infectious Disease
    Apply Pulmonary filter Pulmonary (1) Apply Pulmonary filter
  - Remove Pulmonary Disease filter (-) Remove Pulmonary Disease filter Pulmonary Disease
    Remove Cystic Fibrosis filter (-) Remove Cystic Fibrosis filter Cystic Fibrosis